LINEAR ALKYLBENZENE SULFONATE (LAS) - UNEP Chemicals

OECD SIDS LINEAR ALKYLBENZENE SULFONATE (LAS)
Reliability: 4 This study is assigned a reliability score of 4 because the original report
was not available for review. However, the study was evaluated by IPCS
prior to inclusion in their criteria document.
(e)
Species/strain: Rat (Wistar)
Sex: Female [ ]; Male [X]; Male/Female [ ]; No data [ ]
Administration: oral feed
Exposure period: 2, 4, 12 weeks
Frequency of treatment: Daily in feed
Dose: 1.5% (750 mg/kg bw d)
Control group: Yes [X]; No [ ]; No data [ ];
Concurrent no treatment [ ]; Concurrent vehicle [ ]; Historical [ ]
LOAEL: 1.5% (750 mg/kg bw d)
Results: LAS suppressed body weight gain, and the relative liver weight was
increased from 2 weeks of LAS administration. Serum biochemical
examinations revealed significant increases in ALP and GTP at each
observation period and significant decreases in cholesterol and protein in 4
weeks. Enzymatic examinations of the liver revealed decreases in G6Pase
and G6PDH and an increase in isocitrate dehydrogenase (IDH) at each
observation period. Enzymatic examinations of the renal cortex revealed
decreases in G6Pase and 5'-nucleotidase at each observation period, an
increase in LDH at 12 weeks, and an increase in IDH at 2 and 4 weeks.
Enzymatic examinations in the renal medulla revealed a decrease in NA,K-
ATPase, an increase in LDH at 12 weeks, a decrease in IDH at 2 weeks, and
an increase in IDH at 12 weeks.
GLP: Yes [ ] No [X] ? [ ]
Test substance: LAS (unspecified)
Remarks: Information as cited in IPCS document.
Reference: 1) European Commission. 2000a. Benzenesulfonic acid, C10-13-alkyl derivs.,
sodium salts. Year 2000 CD-ROM edition.
2) Ikawa, M., Yoneyama, M., Nakao, T. and Hiraga, K. 1978. Uptake of
organic acid and organic base by renal cortical slices of rats treated with LAS
and ABS. Ann. Rep. Tokyo Metr. Res. Lab. P.H. 29:51-54 (in Japanese);
cited in: IPCS (1996); Environmental Health Criteria 169: Linear
Alkylbenzene Sulfonates (LAS) and Related Compounds. WHO, Geneva,
Switzerland.
Reliability: 4 This study is assigned a reliability score of 4 because the original report
was not available for review. However, the study was evaluated by IPCS
prior to inclusion in their criteria document.
(f)
Species/strain: Rat (Wistar)
Sex: Female [ ]; Male [ ]; Male/Female [X]; No data [ ]
Administration: oral feed
Exposure period: 6 months
Frequency of treatment: Daily in feed
Dose: 0.07, 0.2, 0.6, 1.8% (40, 115, 340, 1030 mg/kg bw d)
Control group: Yes [X]; No [ ]; No data [ ];
Concurrent no treatment [X]; Concurrent vehicle [ ]; Historical [ ]
NOAEL: = 40 mg/kg bw d
LOEL: = 115 mg/kg bw d
Results: The 1.8% group showed diarrhoea, markedly suppressed growth, increased
weight of the cecum, and remarkable degeneration of the renal tubes. The
0.6% group showed slightly suppressed growth, increased weight of the
cecum, increased activity of serum alkaline phosphatase (ALP), a decrease in
UNEP PUBLICATIONS 273